Batch dependent - please inquire should you have specific requirements.
Buffer
In PBS with 8M Urea
Preservative
None
Storage
Store at 2-8°C for short term (up to 7 days). Store at -20°C for long term. Avoid multiple freeze/thaw cycles
Antigen Description
Venezuelan equine encephalitis is an acute viral disease characterized by fever, chills, headache, nausea, vomiting, lumbosacral pain, and myalgia, which may progress to encephalitis. It is caused by the Venezuelan equine encephalitis virus and is a signi
Have you cited DAGA-268 in a publication? Let us know and earn a reward for your research.
Background
Alphaviruses are important mosquito-borne pathogens in the virus classification group IV (+) ssRNA virus family Togaviridae, causing localized outbreaks and human epidemics. Alphaviruses can be divided into two separate subgroups: old world (OW) and new world (NW). Venezuelan equine encephalitis virus (VEEV) belongs to the New World alphavirus, which is transmitted by mosquitoes and circulates in rodents. It can cause disease in horses and humans and is characterized by a febrile illness that may progress to encephalitis. The prevalent strains of VEEV are categorized into subtypes ID, IE, and II-VI. In humans, VEEV causes moderate flu-like symptoms, including fever, headache, myalgia, fatigue, nausea, and pharyngitis. In a small number of cases, encephalitis leads to severe neurologic complications such as confusion, convulsions, photophobia, and coma, which are fatal in about 1% of cases. The progression of the disease to encephalitis can lead to long-term neurological deficits.
VEEV is approximately 70 nm in diameter and has T=4 icosahedral symmetry. The viral RNA is encapsulated by a 240-copy viral capsid protein bound to the N-terminus of the protein. At the C-terminus, the capsid binds to the E2 glycoprotein. Glycoproteins E1 and E2 form heterodimers and trimers with other E1/E2 dimers and protrude from the viral envelope obtained from the host cell membrane during germination.
Figure 1. 3D reconstruction of VEEV (Source: Zhang R, et al. 2011)
The genome is 11.5kb in length and has two reading frames. The RNA has a 5' cap and a 3' poly-A tail and forms a stem-loop structure at the 5' end that serves as a promoter of replication. The first reading frame begins near the 5' end and encodes four nonstructural proteins (nsP1-4), which are translated into a large polyprotein named P1234. nsP1 is involved in the process of mRNA capping to protect the RNA from cellular nucleases. nsP2 is responsible for regulating the packaging of the viral genome into infectious viral particles. nsP3 interacts with the host and influences viral replication. nsP4 is the RNA-dependent RNA polymerase. Together, these proteins form the enzymatic structures required to transcribe and replicate the viral genome. The second reading frame begins in the center of the genome and is controlled by the 26S promoter on negative-strand RNA, encoding structural proteins including capsid, E1 and E2 envelope proteins. E2 protein is glycosylated and is responsible for receptor-mediated endocytosis. It is not only involved in cell attachment, but also a necessary condition for virus budding. The assembled nucleocapsid migrates to the cell surface and interacts with the C-terminal cytoplasmic domain of E2. This interaction itself provides enough energy for the virus to germinate from the cell.
Figure 2. VEEV particle structure and genome organization (Source: Han L, et al. 2023)
1. Zhang R, et al. 4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J. 2011 Aug 9;30(18):3854-63.
2. Han L, et al. A roadmap for developing Venezuelan equine encephalitis virus (VEEV) vaccines: Lessons from the past, strategies for the future. Int J Biol Macromol. 2023 Aug 1;245:125514.
3. Guzmán-Terán C, et al. S. Venezuelan equine encephalitis virus: the problem is not over for tropical America. Ann Clin Microbiol Antimicrob. 2020 May 19;19(1):19.
My Review for VEEV E2 glycoprotein (aa 348-701) [His]
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
A roadmap for developing Venezuelan equine encephalitis virus (VEEV) vaccines: Lessons from the past, strategies for the future
Int J Biol Macromol
Authors: Han L, Song S, Feng H, Ma J, Wei W, Si F.
Venezuelan equine encephalitis (VEE) is a zoonotic infectious disease caused by the Venezuelan equine encephalitis virus (VEEV), which can lead to severe central nervous system infections in both humans and animals. At present, the medical community does not possess a viable means of addressing VEE, rendering the prevention of the virus a matter of paramount importance. Regarding the prevention and control of VEEV, the implementation of a vaccination program has been recognized as the most efficient strategy. Nevertheless, there are currently no licensed vaccines or drugs available for human use against VEEV. This imperative has led to a surge of interest in vaccine research, with VEEV being a prime focus for researchers in the field. In this paper, we initially present a comprehensive overview of the current taxonomic classification of VEEV and the cellular infection mechanism of the virus. Subsequently, we provide a detailed introduction of the prominent VEEV vaccine types presently available, including inactivated vaccines, live attenuated vaccines, nucleic acid, and virus-like particle vaccines. Moreover, we emphasize the challenges that current VEEV vaccine development faces and suggest urgent measures that must be taken to overcome these obstacles. Notably, based on our latest research, we propose the feasibility of incorporation codon usage bias strategies to create the novel VEEV vaccine. Finally, we prose several areas that future VEEV vaccine development should focus on. Our objective is to encourage collaboration between the medical and veterinary communities, expedite the translation of existing vaccines from laboratory to clinical applications, while also preparing for future outbreaks of new VEEV variants.
Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits
Front Trop Dis
Authors: Tretyakova I, Tomai M, Vasilakos J, Pushko P.
Effective and simple delivery of DNA vaccines remains a key to successful clinical applications. Previously, we developed a novel class of DNA vaccines, sometimes called iDNA, which encodes the whole live-attenuated vaccine viruses. Compared to a standard DNA vaccine, an iDNA vaccine required a low dose to launch a live-attenuated vaccine in vitro or in vivo. The goal of this pilot study was to investigate if iDNA vaccine encoding live-attenuated Venezuelan equine encephalitis virus (VEEV) can be efficiently delivered in vivo by a microneedle device using a single-dose vaccination with naked iDNA plasmid. For this purpose, we used pMG4020 plasmid encoding live-attenuated V4020 vaccine of VEE virus. The V4020 virus contains structural gene rearrangement, as well as attenuating mutations genetically engineered to prevent reversion mutations. The pMG4020 was administered to experimental rabbits by using a hollow microstructured transdermal system (hMTS) microneedle device. No adverse events to vaccination were noted. Animals that received pMG4020 plasmid have successfully seroconverted, with high plaque reduction neutralization test (PRNT) antibody titers, similar to those observed in animals that received V4020 virus in place of the pMG4020 iDNA plasmid. We conclude that naked iDNA vaccine can be successfully delivered in vivo by using a single-dose vaccination with a microneedle device.